Overview
RADX market data
Price History
RADX price chart · 1M
- O
- 2.23
- H
- 2.30
- L
- 2.18
- C
- 2.18
- Vol
- 700.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $2.23
- Previous Close
- $2.45
- Day High
- $2.30
- Day Low
- $2.18
- 52 Week High
- $4.72
- 52 Week Low
- $2.18
- 7 Day Return
- -5.42%
- 30 Day Return
- -32.61%
- 90 Day Return
- -52.51%
- 1 Year Return
- -52.71%
- Daily Notional Volume
- $1.5K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,236.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.01 – $0.04 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $52.1M · P/B 1.16 · P/S 14.32.
Company News
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid TumorsGlobenewswire Inc · Aug 26, 2026, 11:15 AM
Radiopharm Doses First Patient In Second Cohort Of Its First-In-Human Phase 1/2a Clinical Trial Of RV-01 In Patients With B7-H3 Expressing TumorsBenzinga · Aug 26, 2026, 11:09 AM
12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · Aug 24, 2026, 1:28 PM
Radiopharm Theranostics Says Data Safety And Monitoring Committee Recommends Advancing RAD202 To 180mCi Dose Level In Phase 1 HEAT Trial In HER2-Positive Advanced Solid TumorsBenzinga · Aug 20, 2026, 11:25 AM
Radiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design Of A Pivotal Phase 3 Trial To Evaluate RAD101 In Patients With Suspected Recurrence Of Brain Metastases Following RadiotherapyBenzinga · Aug 17, 2026, 11:36 AM
12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · Aug 7, 2026, 9:05 PM
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Jul 24, 2026, 5:05 PM
US Stocks Mixed; American Express Shares Fall Following Q2 ResultsBenzinga · Jul 24, 2026, 1:45 PM
Radiopharm Theranostics Announces $4.1M U.S. Direct Offering Of Shares And Warrants Along With A$12.7M ($8.9M) Australian PlacementBenzinga · Jul 24, 2026, 11:18 AM
Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jul 24, 2026, 11:00 AM